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T he coronavirus (COVID-19) pandemic continues torapidly and dramatically transform the daily lives of
patients and health care providers across the world. The
number of new cases even at the time of this writing con-
tinues to grow. As individuals and as physicians, we have
a responsibility to our patients and to society to “first, do no
harm.” As such, neuro-ophthalmologists must balance their
sacred oath to “treat the sick” against the need for social
distancing to help “flatten the disease curve.” The American
Academy of Ophthalmology (AAO), the American Acad-
emy of Neurology (AAN), the Centers for Disease Control
and Prevention (CDC), the World Health Organization
(WHO), and other public health organizations have actively
updated recommendations and have suggested practices and
protocols that may be of interest to practicing ophthalmol-
ogists. The AAO’s early guidelines recommended that oph-
thalmologists defer any routine or nonurgent appointments
in the clinic and postpone all elective surgical cases (see
Supplemental Digital Content 1, Table E1, http://links.
lww.com/WNO/A422). Thus, we have a responsibility to
appropriately triage new and returning patients to ensure
the safety of providers, patients, and the general public
during and following this unprecedented pandemic.
Neuro-ophthalmologists, however, often diagnose vision-
threatening and potentially life-threatening disease, and
delay in diagnosis or treatment can be devastating. There-
fore, alternatives have been proposed to balance our com-
peting interests of individual patient and provider safety
from COVID-19 against the potential risk of undiagnosed
or untreated neuro-ophthalmic disease.
Recent expansion of telehealth benefits for Medicare
patients allows and encourages neuro-ophthalmologists to
integrate telemedicine into practice (1). The North American
Neuro-Ophthalmology Society (NANOS) has supported the
use of telehealth in practice, and the reader is referred to the
NANOS website for updates, resources, and webinars for the
instruction of telemedicine skills for neuro-ophthalmologists.
Furthermore, there is no doubt that neuro-ophthalmologists
are widely recognized as a scarce resource. According to a recent
NANOS membership survey of US practicing physicians, there
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are 1.75 million people per 1.0 CFTE neuro-ophthalmologist,
and only 187 total practicing CFTE in the nation (2). With an
average wait time of 6 weeks, and with over 30% of survey
respondents reporting over 3-month wait times, telemedicine is
an intriguing alternative for patients from poorly represented
regions of the country.
In this article, we present possible “best practices” for
neuro-ophthalmologists to design and implement tele-
neuro-ophthalmology during and following this national
and international crisis. We review the previsit, intravisit,
and postvisit steps in a practical manner that we hope will
be of value to practicing neuro-ophthalmologists. We
include sections on how to appropriately implement tele-
medicine and patient selection, focusing on different types
of visits, determining eligible patients, and triaging patients.
In addition, we outline the software and hardware require-
ments for the electronic medical record (EMR), including
Epic and non-Epic platforms. We also describe the nuts and
bolts of how to get started, including descriptions of the
multiple useful applications and software available. As with
any medical encounter, privacy regulations, billing, and
coding can be significant hurdles to implementation, and
we discuss each in detail. We hope that this article will be of
use for neuro-ophthalmologists, comprehensive ophthal-
mologists, and general neurologists because we deal with
effects and aftereffects of this COVID-19 pandemic. We
believe that this current disruptive innovation will drive the




The terms “telehealth” and “telemedicine” are used inter-
changeably in this article because there is a significant inter-
agency variation in and continual evolution of these
concepts and associated technology modalities. Face-to-
face telemedicine encounters between the provider and
the patient are conducted through synchronous (live real-
time) interaction through electronic audio and video plat-
forms. Email or other time delayed methods (a.k.a. “asyn-
chronous” or “store and forward”) address information
electronically stored and used for patient communication,
information gathering or dissemination, or provider-to-
provider consultation (“E-consults”). Specific telemedicine
terminology is detailed in Supplemental Digital Content 1
(see Table E2, http://links.lww.com/WNO/A422). Institu-
tional consideration for telemedicine is described in Sup-
plemental Digital Content 1 (see Table E3, http://links.
lww.com/WNO/A422). Indications for each of the main
modalities of telehealth delivery are described here (also,
see Supplemental Digital Content 1, Table E4, http://
links.lww.com/WNO/A422).
When to Consider a Video Visit
Video visit is optimal for those who desire a more personal
connection to their provider and for external examinations.
Although suboptimal compared with an in-person exami-
nation, especially for patients with suspected optic neurop-
athies with subjective vision changes, returning patients
may still find comfort, counsel, and education from the
clinician over video. In many cases, an in-person eye
examination has already been performed elsewhere, and
the neuro-ophthalmic virtual video visit is more of an
informative review to discuss diagnostic findings, educate,
and plan rather than to repeat the examination. Outside
visual field testing, ocular imaging, and neuroimaging can
still be presented visually to the patient in a virtual visit
through screen-sharing. Video visits can also be particularly
useful for visualizing an external lid, strabismus, or orbital
problem (e.g., ophthalmoplegia, ptosis, or proptosis). The
clinician can instruct the patient to demonstrate any neuro-
ophthalmic signs over video platforms (e.g., ocular motility
examination or even ice pack testing for myasthenia gravis).
Synchronous video telemedicine is the best mimic of an in-
person clinic visit, and it may have value in simply fostering
uninterrupted time to consult one-on-one with the
physician.
When to Consider Phone Visits
Phone visits may be used for the follow-up of a patient
who has a known pathology with subjective outcome
measures, such as ischemic cranial nerve palsy with
accompanying diplopia, which is expected to recover
over 6–12 weeks. If the diplopia is not recovered, the
patient can then be brought into clinic or undergo fur-
ther remote video visits to assess clinical progress. Phone
visits also offer an opportunity for providers to adjust
medications for patients with migraines or myasthenia
gravis. In addition, a physician can use phone visits to
triage visual symptoms with a normal dilated eye exam-
ination by another provider or discuss medication com-
pliance and tolerance, neuroimaging findings, and
laboratory test results.
When to Consider Email or Online Portal
Communication
Established patients may decide to reach out through email
or online (EMR) portal regarding their condition. This
modality, because it is not real time, is best suited for
communications that are not as time-sensitive (e.g., med-
ication refills, test results, treatment plans, overall condition,
or scheduling). Online portal communication can also aid
in sharing photographs or videos (e.g., external examination
findings, OCT, or visual fields) to aid in clinical evaluation.
If there is a question or concern raised by the patient that
may be better addressed in real time, a video or phone visit
may then be undertaken.
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When to Consider Provider-to-Provider
Consultation (“E-consult”)
Neuro-ophthalmologists are often asked by other providers to
provide consultations regarding the diagnosis or management
of a patient but without the expectation of a clinic appointment
(the so-called curbside consultation). This may be preferable for
patients located in remote areas, who already have an engaged
clinician. In an e-consult, the neuro-ophthalmologist would
review clinical records and imaging, and then provide a written
summary of impressions and recommendations to the referring
provider. This option is ideal if the neuro-ophthalmologist
determines that the patient requires related testing or medical
care before an appointment or does not need their in-person
examination (Fig. 1).
Selecting Appropriate Patients for
Telemedicine Services
Selecting cases in neuro-ophthalmology that can be seen
safely and effectively through telemedicine is a controversial
discussion, but necessary given the COVID-19–related social
distancing restrictions and need to maintain access to neuro-
ophthalmic care. Particularly, as clinics recover from these
restrictions, poor access to specialty care will be further lim-
ited, necessitating options for “work-arounds” to traditional
clinic schedules. Some general guidelines for patient selection




In a national crisis such as the current COVID-19
pandemic, the normal triage techniques for appropriate
patients may no longer apply in some cases. Before
COVID-19, a telemedicine visit might follow an initial
in-person visit: the patient could complete local visual field
testing, fundus photographs, OCT, and/or MRI, and then
review the results with the neuro-ophthalmologist over
phone or video as the case history is discussed. In this
setting, the neuro-ophthalmologist could use a majority of
the information normally gleaned from an in-person
examination. Nevertheless, this format may not be possible
during a health crisis requiring social distancing in all
clinical settings (i.e., no ancillary testing). Thus, what can
be seen on videos and gleaned from history is perhaps all the
information one may have to make a clinical workup or
treatment decision.
For new referrals, the neuro-ophthalmologist may be
forced to rely on the review of the patient’s previous medical
records and ancillary testing to determine whether the
patient urgently needs to be seen in-person. Before
COVID-19, the solution was generally “send them to the
clinic” for the neuro-ophthalmologist to perform the initial
evaluation before coordinating care; now, some coordina-
tion of care may need to precede the face-to-face evaluation.
Just as general neurologists and ophthalmologists are trained
FIG. 1. Choosing the appropriate type of telemedicine visit. *New telephone consults with patients are not typically a cov-
ered service. DFE, dilated fundus examination.
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to order laboratory testing in suspected giant cell arteritis
before the patient may see a neuro-ophthalmologist, there
are other situations in which a neuro-ophthalmologist may
be able to direct referring providers in obtaining appropriate
testing before an in-person evaluation. Telemedicine serv-
ices such as the interprofessional consultation or live video
telemedicine evaluation may allow the neuro-
ophthalmologist to obtain sufficient data to make a reason-
able recommendation on management, effectively reducing
the risk of virus exposure by coordinating the patient’s care
more efficiently. The neuro-ophthalmologist may still elect
to evaluate the patient in-person if necessary. The level of
urgency dictates the type of visits available to the patient
(e.g., in-person examination, video telemedicine visit,
phone telemedicine visit, and interprofessional consulta-
tion) and the timeframe for management.
The decision as to whether to bring a patient into the
clinic for evaluation should also take into account the
potential for harm should the patient be exposed to and
infected with COVID-19. For example, a 32-year-old
healthy patient with a complaint suggesting a low likelihood
of serious pathology might still be worth bringing in for
evaluation to rule out such pathology, whereas an 82-year-
old patient with diabetes who is at high risk of mortality
from COVID-19 might be better served with an initial
video visit.
Many subspecialties have provided general triage guid-
ance for their providers (3). In neuro-ophthalmology, prac-
tice patterns vary greatly; thus, triage guidelines may vary
between geographic regions, institutional capabilities, and
individual patient situations. Although definitions of
urgency will differ from provider to provider, telemedicine
can be an effective tool for urgent triage and assessment,
potentially moving a patient between categories of urgency
more accurately. The specific modality choice is based on
whether quick access to accurate history or seeing the exter-
nal examination is paramount to determine next steps in
care. Combining various modalities may improve efficacy:
phone for triaging patient complaints and determining
urgency, then an in-person appointment for assessment,
and perhaps a follow-up visit by video once the video plat-
form has been successfully established and the patient is
clinically stable. The availability of ancillary testing will
determine the ability to follow a patient remotely for optic
nerve pathology, such as with idiopathic intracranial hyper-
tension, which, in addition to history, requires a fundus
view, a visual field, and arguably an OCT to determine
clinical stability. In all these clinical situations, the physician
may be able to use telemedicine tools to enhance their reach
across practice settings, leading to potentially superior care,
higher patient satisfaction, and, in the case of COVID-19,
a safer environment for all.
FIG. 2. Coding for telemedicine services.
4 Lai et al: J Neuro-Ophthalmol 2020; 00: 1-13
Perspective




The choice of software and hardware for tele-neuro-
ophthalmology is highly practice or institution dependent.
If the institution already has a telemedicine platform that is
integrated into the electronic health record (EMR), then the
choice is clear and simple. Many institutions, however, may
be overwhelmed with onboarding high volumes of providers
to their integrated telemedicine platform. Recent changes in
the policies and procedures of the Health and Human
Services (HHS) Office for Civil Rights (OCR) have led to
waiving of penalties for Health Insurance Portability and
Accountability Act (HIPAA) violations against health care
providers, assuming that they serve patients in good faith.
This change allows telemedicine providers to communicate
using everyday communication technologies and has per-
mitted for the use of third-party platform applications
during the COVID-19 nationwide public health emergency
(4). There are many third-party platform applications avail-
able; however, we are highlighting one representative tech-
nology in this monograph (doxy.me) (5). Doxy.me is free, is
HIPAA compliant, and includes a business associate agree-
ment (BAA) that is easy to use for both provider and
patient.
Other free platforms, however, include Zoom, Cisco
Webex, Skype, and Apple FaceTime, but depending on the
version that is selected, clinicians should be aware of issues
regarding cost, security, and patient privacy. For example,
the free version of Zoom automatically ends the call at
40 minutes if there are more than 3 participants on the call.
For full service, one would need to purchase Zoom Pro or
Zoom for Healthcare. Clinicians should also consider
choosing a platform that is HIPAA compliant (e.g.,
FaceTime and Skype are not compliant) to avoid compli-
ance issues and/or penalties after the pandemic emergency
has ended when the exemptions may be reversed. The Texas
Medical Association has also compiled a list of third-party
vendors, which includes features and pricing information
(see Supplemental Digital Content 1, Table E6, http://
links.lww.com/WNO/A422) (5).
For the purpose of educating residents or fellows, there is
an advantage to platforms that allow more than 2
participants, such as Zoom, so that the resident may join
on the visit, with the patient’s permission, as part of their
resident education. Understanding the setup and needs of
one’s practice will dictate the best type of third-party tele-
medicine platform. For example, if one already has an ex-
isting EHR and does not want to invest in a telemedicine
platform that requires integration with that EHR, obtaining
a platform that is independent for a low monthly fee may
make most financial sense (e.g., doxy.me and Zoom for
Healthcare). If one seeks full integration of appointment
scheduling, EHR, telemedicine visits, electronic medication
orders, and patient portal communication, other platforms
(e.g., AmWell, NextGen, and Zipnosis) offer more compre-
hensive services. Hardware requirements and some general
guidelines for the setup are included in Supplemental Dig-
ital Content 2 (see Data E1, http://links.lww.com/WNO/
A423). The authors are not endorsing any specific vendor,
the accuracy, or timeliness of this compilation.
TELEMEDICINE USING EPIC AND NON-
EPIC PLATFORMS
Connecting With the Patient: Implementation of
Technology for Telehealth Neuro-
Ophthalmology Visits
The mechanism used for establishing a video connection
with the patient to perform a virtual visit will depend on
whether your institution or practice uses Epic and whether
telehealth platforms have been formalized and embedded
into the Epic system.
Before initiation of a telemedicine visit, patient consent
is required and must be documented. As a result, you
should obtain and document patient consent in the chart
before every telemedicine visit. Below is sample language
that you can use:
“This is a telemedicine visit that was performed
with the originating site at [INSERT PATIENT
LOCATION] and the distant site at [INSERT
PROVIDER LOCATION]. Verbal consent to
participate in video visit was obtained. This visit
occurred during the Coronavirus (COVID-19)
Public Health Emergency. I discussed with the
patient the nature of our telemedicine visits and
its inherent limitations, that: I would evaluate the
patient and recommend diagnostics and treat-
ments based on my assessment. Our sessions are
not being recorded and that personal health infor-
mation is protected. Our team would provide
follow-up care in person if/when the patient needs
it.”
Virtual Visits Through Epic in a Formalized and
Embedded System
Differences in Epic functionality and appearance may vary
across medical centers and practices; thus, what follows
serves as an example of how the system appears and
functions at a single institution. A prerequisite for provision
of virtual visits in Epic is setting up Epic on either an
iPhone or iPad. Although Epic can be set up on Android
phones, in this institution’s example, Android phones can-
not currently be used for virtual visits. The Epic application
for iPhone use is called Haiku (see Supplemental Digital
Content 3, Figure E1, http://links.lww.com/WNO/A411)
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and for iPad use is called Canto. The process of obtaining
Haiku on the iPhone or Canto on the iPad, in this example,
involves first downloading an application in the App Store
called “Intelligent Hub” that allows installation of a program
called “AirWatch.” This allows for remote management of
work-related applications and is often the mechanism by
which work email is obtained on a smartphone. Therefore,
it may already exist on your phone if you receive your work
email on your phone. Once installed, the Haiku or Canto
application must be set up in Settings to allow for notifica-
tions. For those at academic medical centers, the informa-
tion technology department is typically available to assist.
Once Haiku or Canto exists on your iPhone or iPad,
respectively, virtual visits may occur using that device.
When administrative staff schedule a patient for a virtual
visit, these virtual visits are noted on the clinic schedule as
a “Video Visit” type, and a video camera symbol can be seen
on the schedule on Haiku, Canto, or the typical PC Epic
schedule (see Supplemental Digital Contents 4 and 5,
Figure E2A and E2B, http://links.lww.com/WNO/A412,
and http://links.lww.com/WNO/A413). This visit type can
occur within an existing face-to-face clinic schedule or on
a day consisting of virtual visits alone. An example of such
an embedded schedule is the following: a new face-to-face
patient at 9 AM, an established patient virtual video visit at
10 AM, an established face-to-face patient at 10:30 AM, etc.
The video visit duration will be set on your schedule for the
duration that you set for new and established visits, but as in
a face-to-face visit, the duration of the visit just holds the
spot on the schedule. Once the video visit is started, the
video call does not automatically disconnect at any point.
You will terminate the call only when the visit is completed.
The prerequisite for the patient to have a virtual visit
through Epic is for them to have an active online portal
account. At the time of scheduling, the patient is instructed
to sign on for the visit 15 minutes before the visit time, so
that they are ready and waiting in the virtual “waiting
room” when the appointment time arrives. When the
patient is connected, the video icon on the Epic schedule
turns green on both desktop Epic and Haiku/Canto (see
Supplemental Digital Content 6, Figure E2C, http://
links.lww.com/WNO/A414), and a push notification ap-
pears on the iPhone or iPad that the physician will use
for the video visit (see Supplemental Digital Content 7,
Figure E3A, http://links.lww.com/WNO/A425).
Reminder push notifications are sent at specific intervals
until the physician connects with the patient. When ready
to connect with the patient for the visit, the physician may
either connect to the patient directly from Haiku/Canto or
log onto desktop Epic as usual on either a desktop PC or
laptop and click on the patient’s visit on the schedule to
open the chart. If logging onto desktop PC first, a “Handoff
to Haiku/Canto” button will be present in the upper left
corner (see Supplemental Digital Content 8, Figure E3B,
http://links.lww.com/WNO/A415). Pushing this button
will activate the iPhone/iPad, allow for Haiku/Canto log
on, and connection to the patient through the “Join Video
Call” button in iPhone/iPad (see Supplemental Digital
Content 9, Figure E3C, http://links.lww.com/WNO/
A416). The video visit proceeds on the iPhone/iPad, and
documentation is completed on desktop Epic.
Virtual Visits Through a Third-Party App
Supplemental Digital Content 10 (Data E2, http://links.
lww.com/WNO/A424) includes specific tips on using these
applications. Depending on the third-party platform, a con-
sent form may not be available or integrated into the
workflow.
Doxy.me
Go to https://doxy.me/sign-up on your phone, tablet, or
computer. Complete all fields and click sign up (see Sup-
plemental Digital Content 11, Figure E4, http://links.
lww.com/WNO/A417). Under account settings, you may
select the tab “BAA” to generate a BAA if applicable. You
can also select the checkbox “I don’t need a BAA.” The
telemedicine visit with your patient through doxy.me will
work irrespective of your choice regarding a BAA.
You will then be logged into your dashboard, and you
will be provided a room name link, doxy.me/(the room
name you have selected), which will need to be provided to
your patients so that they can connect with you at the time
of their scheduled appointment (see Supplemental Digital
Content 12, Figure E5, http://links.lww.com/WNO/
A418). The patient does not need to download any software
or create an account within doxy.me. Their sessions are
anonymous, and none of their information is stored. They
only need to enter your room link into their web browser,
type their name, and select “check in” (see Supplemental
Digital Content 13, Figure E6, http://links.lww.com/
WNO/A419).
Before the appointment time, you can run a Pre-call Test
(see Supplemental Digital Content 14, Figure E7, http://
links.lww.com/WNO/A420) whereby doxy.me will run di-
agnostics on your device, including video and audio quality
and stability. When the patient arrives into the virtual wait-
ing room, you will see their image in the upper left corner
under the “patient queue.” From your mobile device or
tablet, you will see a red circle in the upper left corner when
a patient is waiting to see you. You can click on the red dot
area and, when ready, click the patient’s name to start the
video. If you are on a computer, click “start call.” Then,
select “video call” to begin the visit. Always allow the use of
your camera and microphone. When the video begins, the
patient will be on the large screen and the provider will be
on the smaller screen. If you hit “pause the video,” you will
send the patient back into the “waiting room.” Once your
visit is complete, you can hang up the call with the red
telephone icon.
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Applications for Home Testing
A challenge that many providers identify with telemedicine
and remote evaluations is the physical examination and
other objective data collection. Although remote physical
and ocular examinations are not as useful as those in-person,
there are a number of technological outlets to simplify and
optimize home testing through telemedicine. Multiple
smartphone and tablet applications have been validated
for remote visual acuity testing. Patients with Android
Galaxy phones and someone to help, as the phone is held
2 m away, can use “PEEK Acuity,” a free app validated for
distance testing (6,7) and use in children (8). Patients who
have Apple iPhone 7 Plus or who do not have an assistant
available can use “Vision@home,” an online test validated
for both near (40 cm) and distance (2 m, assistant needed)
visual acuities that is accessible free on their phone browser
at www.visionathome.com.au (9). For Apple iPad tablet
users, “Eye Chart Pro” is a free app validated for distance
vision (2.5 m, assistant needed) (10) on the iPad and avail-
able but not validated on the iPhone. “Visual Acuity XL”
has also been validated for distance vision (held at 6 m)
using the iPad (11), although its accuracy is highly suscep-
tible to glare and it costs $75. Notably, the commonly used
app “Eye Handbook,” available for Apple iPad and Android
users, has a near card test that may overestimate near VA
(12). Refer to Table 1 for a review of the findings of each
visual acuity application validation study.
Smartphone applications exist for color vision testing,
although options are more limited and are hampered by
variation in tablet display manufacturing parameters (13).
The most promising is contained within the “Eye Hand-
book” app, which is available free for both Apple iPhone
and Android users. The app was validated against the Ishi-
hara color vision test in 2 clinical studies (14,15), although
a nonclinical study using image analysis found it likely
underestimates color vision loss severity in patients with
normal contrast sensitivity (CS) and does not contain as
many specially designed plates as Ishihara for differentiation
of R-G deficiency from total color blindness (8). Other less
promising apps include “Color Blind Test” (16) and “Color
Vision Test” (17). Refer to Table 2 for color validation
studies. At the moment, these apps can only approximate
a color perception test and detailed color testing needs to be
performed in-person.
Regarding perimetry, 2 apps “MRF Glaucoma Lite” and
“MRF Neuro Lite” provide reliable Apple iPad–based
threshold perimetry, and “eyesimplify.com” uses the same
technology in a computer browser form. MRF Glaucoma
Lite tests the central 30° horizontally and 20° vertically by
implementing a radial testing grid and changing the loca-
tion of the fixation point held approximately 33 cm away
(18). Stimuli have an operating range of 0 dB–30 dB and
increase in size with eccentricity from Goldmann size III to
IV with a background luminance of 5 cd/m2 (15.71 asb).
Unexpectedly, altering ambient lighting and viewing dis-
tance (between 25 cm and 75 cm) did not affect the
threshold in a small group of testing subjects (18). All MRF
measurements were highly correlated with those of the 24-2
Humphrey Field Analyzer (HFA) across multiple inves-
tigations (19–22), showing reliability and reproducibility
over multiple visits (20–22), strong sensitivity and speci-
ficity (20), and faster testing speed than the HFA SITA-
Standard (comparable with the HFA SITA-Fast) (21,22).
Notably, the proportion of fixation losses is found to be
higher and more variable than the HFA (22,23). The most
recent MRF technology has been licensed to “eye-
simplify.com” and released for beta testing in a home
computer browser version found at the aforementioned
website. This version allows testing of either the 24-2 or the
10-2 visual field and may shortly be accessible on iPad or
Android. “Visual Fields Easy,” the predecessor to the MRF
programs, is another free iPad application; it does supra-
threshold screening visual fields of the central 60° hori-
zontally and 48° vertically at a background luminance of 10
cd/m2 (31.5 asb) of the iPad with size V Goldmann
equivalent stimulus at 16 dB intensity. Johnson et al found
that “Visual Fields Easy” detected most visual defects with
moderate to advanced loss as seen on SITA-standard testing
but had difficulty identifying loss of less than 6 dB (19,24).
Unfortunately, to our knowledge, no validated perimetry
testing applications exist for patients with Android,
although patients without Apple iPads have access to
“eyesimplify.com” on a home computer browser. Tablet-
based perimetry has the potential to cut detection of rapid
visual loss in glaucoma from 2.5 years to 0.9 years with
more frequent testing (25), bring access to necessary visual
field testing to bed-bound hospital patients (26), and
transform remote and home testing (23). Refer to Table 3
for findings of the studies validating tablet-based perimetry
against the HFA.
CS offers an additional means of assessment of optic
nerve and macular function and has been shown to correlate
with optic nerve thickness following optic neuritis. CS may
be tested remotely, using VCStest.com, which uses gray and
white grids of varying degrees of contrast and size and pro-
vides a comprehensive report or with the CS letter chart
available on the Eye Handbook app. The reliability of CS is
particularly sensitive to screen brightness, so online assess-
ments should be interpreted as screening tests rather than




National and institutional regulations should be considered
to avoid privacy and legal infringements. Many larger
institutions have dedicated telemedicine implementation
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staff who can support the roll-out of telemedicine services.
For those in smaller groups or in private practice, there may
be less bureaucracy, but national and state regulations still
exist. It may be necessary to consult a health care policy
lawyer before embarking on a new patient communication
platform. During the COVID-19 pandemic, many of the
previous barriers in implementing telemedicine have been
suspended, but they will likely resume after the resolution of
this crisis.
Privacy and Security
Conceptually, technological privacy and security refer to
how the user (doctor–patient), the company providing the
platform (e.g., Zoom and Google), and everyone else on the
internet (external parties) relate to each other (see Supple-
mental Digital Content 15, Figure E8, http://links.lww.
com/WNO/A421). Security is the term used to describe
a company’s ability to protect the consumer from external
parties’ access of unauthorized data. Privacy refers to the
company’s user-allowed rights to access, store, and share
user data (27). One might think of security as “putting
locks on the door” and privacy as “putting curtains on
the windows.”
In the context of health care, security sets the standards
for ensuring that only those who should have access to
personal health information will actually have access.
Privacy has additional stipulations. The 1996 Health
Insurance Portability and Accountability Act (HIPAA)
requires “appropriate safeguards to protect the privacy of
personal health information, and sets limits and conditions
on the uses and disclosures that may be made of such
information without patient authorization” (28). Translat-
ing this to telemedicine, the HIPAA requires the visit be as
secure and confidential as an in-person appointment and is
achieved through the following elements:
• The patient must consent to use of telemedicine technol-
ogy to conduct a health care visit (and its associated
billing).
• The interaction should be made on a secure provider-to-
patient platform with encrypted data exchange.
• Video or audio should not be recorded or discoverable
(one could imagine that recordings or screenshots with
express patient written consent for treatment purposes
could be allowable).
Each institution may have their own platforms with
associated training modules and signed contracts required
for use; for example, the VA Health Care System uses the
secure “VA Video Connect,” or VVC platform, with ded-
icated talent management system prerequisite training and
telework agreements (29). According to recent advice from
the Office of Civil Rights (OCR) at the Department of
Health and Human Services (HHS), covered health care
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TABLE 3. Tablet-based perimetry vs Humphrey Field Analyzer review




With HFA Repeatability Speed Comments
MRF Glaucoma Threshold
perimetry




MD r2 = 0.80
PSD r2 = 0.77
























































Johnson et al (19) HFA SITA-Standard
24-2
MD r = 0.79
PSD r = 0.60
TD r = 0.51
PD r = 0.68

























AUC, area under the curve; HFA, Humphrey Field Analyzer; ICC, intraclass correlation coefficient; MD, mean deviation; MRF, Melbourne Rapid Fields; PD, pattern deviation; PSD, pattern SD;


















































non–public-facing remote communication product that is
available to communicate with patients during the COVID-
19 nationwide public health emergency. In other words, the
OCR is currently exercising its discretion not to audit tele-
medicine encounters for HIPAA violations, allowing pro-
viders to avoid penalties for noncompliance with the
HIPAA rules, when the “good faith” provision of telehealth
is used (30).
Despite the relaxation of HIPAA enforcement, clinicians
should be careful to select communication platforms with
“lockable rooms” to protect patient–doctor privacy in this
unique clinical care format. Definitions of security and
privacy vary between technology companies; carefully
reading the service agreements is critical for ensuring that
the platform is appropriate for telemedicine use. Companies
that offer “HIPAA-compliant” services require a BAA,
which is a legal contract between the company offering the
platform and the company using the service (such as
a hospital, clinic, or physician practice) in which both
parties agree to maintain HIPAA-compliant storage and
transmission of patient data. Because some companies offer
both “secure” services that are not HIPAA-compliant and
separate HIPAA-compliant services, it is important to select
the appropriate option to avoid encounters that do not
maintain patient privacy.
Medical Malpractice Liability
It is important to ensure that telemedicine services are
covered by malpractice insurance. Although many carriers
may have implicit or explicit clauses, there may be
limitations on the amount of telemedicine that can be
performed or whether the telemedicine services can be
performed over state lines. Other malpractice insurance
companies may require a separate policy for telemedicine
services.
Medical Licensure
In the United States, medical licenses are typically limited to
specific states; separate licenses are required to practice in
multiple states, with some exceptions allowed within certain
institutions. Some states required providers performing
telemedicine services to hold separate medical licenses.
COVID-19 emergency provisions temporarily suspended
these limitations, allowing physicians or other health care
professionals to provide medical care in any state as long as
they hold a valid equivalent license with a state (31). These
provisions also deemed credentialing requirements at hos-
pitals or other health care facilities nonenforceable during
the crisis.
Billing and Coding
One of the previous barriers to the utilization of tele-
medicine in neuro-ophthalmology has been reimbursement
for services. Before the COVID-19 pandemic, insurers (e.g.,
Medicare, Medicaid, or private insurance in the United
States) placed severe restrictions on telemedicine use, with
many forms of telemedicine not being reimbursable at all
(32). Because of the increased need for telemedicine since
the outbreak of COVID-19 to limit in-person patient en-
counters to urgent/emergent problems, the CMS expanded
its reimbursement of the existing telemedicine codes,1
encouraged private insurers to do the same, added reim-
bursement of telephone evaluation/management codes
(99441–99443), and, in some cases, announced non-
enforcement of certain rules, such as the established patient
requirement for G2010, G2012, and 99421–99423 codes
(4) and HIPAA requirements for live video telemedicine
evaluations (33). Examination requirements for billing of
real-time video telemedicine (99201–99215) was also
changed to allow billing based on time alone or medical
decision making alone, and eye examination codes (92002
and 92012) were later made available for video telemedicine
encounters (34). Although many of these policy changes are
limited to the duration of the current emergency declara-
tion, the expansion of reimbursement of these services has
accelerated the adoption and implementation of tele-
medicine services across all specialties. The CMS has up-
dated and clarified their coding guidelines at least once per
week since March 7, 2020; as such, the guidelines provided
in this document are rapidly evolving.
The AAO and AAN have released coding guidelines for
the billing of telemedicine-related codes during the
COVID-19 emergency (34,35). There are essentially 6 spe-
cific categories of telemedicine services as follows:
• Live, real-time video consults with patients;
• “Virtual check-in” evaluations with established patients
for new problems;
• Evaluation of patient-sent photographs or videos (remote
data interpretation);
• Interprofessional consultation (“E-consult”);
• Online patient communications (e.g., online portals and
secure email);
• Telephone evaluation and management.
Choosing the correct code depends on the type of
communication (Fig. 2), whether it satisfies the CMS re-
quirements (see Supplemental Digital Content 16, Table
E7, http://links.lww.com/WNO/A422), and time spent
(see Supplemental Digital Content 17, Tables E8–E10,
http://links.lww.com/WNO/A422). Additional resources
for neuro-ophthalmologists can be found at https://www.
nanosweb.org/telemedicine.
CONCLUSION
The unprecedented COVID-19 pandemic has created
challenge, hardship, and disruption to the lives and practice
of medicine including neuro-ophthalmology. The full
effects of the crisis remain to be seen, and there will be
long-term implications and downstream consequences for
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neuro-ophthalmology. Disruption, however, sometimes
brings innovation and speeds adoption, and we believe that
the development, refinement, and implementation of tele-
neuro-ophthalmology have been forced to accelerate in
response to the unexpected spike in demand created by
social distancing requirements. The new development and
implementation of telemedicine is instrumental at a time
like this to provide adequate care to all patients while also
trying to “flatten the curve.” While selecting patients and
implementing telehealth into our daily practice, we must
consider all institutional rules and regulations to avoid pri-
vacy and legal infringements, as well as consider different
modalities and formats of providing care. It is important to
consider the AAO guidelines to determine how to appro-
priately triage patients. There are a number of technological
requirements including software, hardware, and Internet for
the process to be optimized. One of the many challenges of
telemedicine is the objective examination of the patient
virtually—although limited, there are multiple good op-
tions, including visual fields and color vision testing, for
objectifying important measures to help assess a patient
remotely. In addition, we outline how to appropriately bill
and code for these virtual visits, as the mechanics differ
invariably from in-person appointments.
The COVID-19 pandemic has been a transformative
disruption both to society and to the practice of medicine.
Although telemedicine existed before the COVID-19
pandemic, the rate of adoption, innovation, and imple-
mentation as a solution to social distancing has been
dramatic, and the use of telemedicine in our neuro-
ophthalmic practices likely will continue long after the
pandemic ends.
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